PharVision Advisers’s Sinclair Inc SBGI Stock Holding History

PharVision Advisers’s Portfolio SBGI Stock Details SBGI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,562	Closed	-$192K	–	544
2025 Q4	$192K	Buy	+12,562	New	+$187K	0.1%	573

Other funds holding SBGI

GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

Converium Capital Montreal $783M AUM

PharVision Advisers's SBGI Position: Q1 2026 in Review

PharVision Advisers sold out of Sinclair Inc (SBGI) in Q1 2026, closing a stake of 12,562 shares — an estimated $192K sold.

PharVision Advisers first reported a position in SBGI in Q4 2025 and held it in 1 quarter. The position peaked at $192K in Q4 2025. 170 funds tracked by Wall St. Rank hold SBGI as of Q1 2026.

PharVision Advisers reported no remaining Sinclair Inc position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 12,562 Sinclair Inc shares in Q1 2026, an estimated $192K.
PharVision Advisers first reported a position in Sinclair Inc in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Sinclair Inc position peaked at $192K in Q4 2025.
170 funds tracked by Wall St. Rank held Sinclair Inc as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.